Retrospective investigation of tacrolimus combined with an anti‐tumor necrosis factorα antibody as remission induction therapy for refractory ulcerative colitis: Efficacy, safety, and relapse rate

BACKGROUND AND AIM: Combined therapy with tacrolimus (TAC) and an anti‐tumor necrosis factorα (TNFα) antibody is used to induce remission in ulcerative colitis (UC) patients who have not responded to monotherapy with either drug. We evaluated the efficacy and safety of combined therapy, as well as t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Ayumi, Omori, Teppei, Nakamura, Shinichi, Tokushige, Katsutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891029/
https://www.ncbi.nlm.nih.gov/pubmed/31832554
http://dx.doi.org/10.1002/jgh3.12197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891029/
https://www.ncbi.nlm.nih.gov/pubmed/31832554
http://dx.doi.org/10.1002/jgh3.12197

Ejemplares similares